The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Injectable Targeted Therapy Market Over The 2026–2030 Period?
The injectable targeted therapy market size has seen swift expansion in recent years. Its valuation is projected to increase from $64.22 billion in 2025 to $71.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The expansion observed in the past can be credited to increasing cancer incidence rates, advancements in monoclonal antibody development, growing adoption of biologic therapies, expansion of oncology treatment centers, and increased clinical research activity in targeted drugs.
The market size for injectable targeted therapy is anticipated to show rapid expansion over the coming years. It is projected to climb to $105.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. The forecasted growth can be linked to the increasing approvals of targeted injectable therapies, growing investments in personalized medicine, an expansion in biologics manufacturing capacity, an intensified focus on immunotherapy development, and a rising demand for precision treatment protocols. Key trends during the forecast period involve the increasing development of precision oncology injectables, a rising uptake of antibody-based therapeutics, a greater focus on targeted drug delivery systems, the expansion of combination injectable therapies, and an enhanced emphasis on reducing off-target toxicity.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp
What Drivers Are Expected To Influence The Injectable Targeted Therapy Market During The Forecast Period?
The rising need for personalized medicine is projected to fuel the expansion of the injectable targeted therapy market in the future. Personalized medicine is defined as a healthcare strategy that customizes prevention, diagnosis, and treatment based on an individual’s genetic makeup, environmental influences, and lifestyle choices. The rise in personalized medicine is fueled by advancements in genomics, which provide a more profound insight into individual genetic variations, thereby facilitating more accurate, targeted treatments that enhance patient results and reduce therapeutic guesswork. Injectable targeted therapy supports personalized medicine by delivering medications specifically aimed at a patient’s distinct molecular or genetic disease characteristics, boosting effectiveness and reducing adverse reactions. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023, the FDA sanctioned 16 novel personalized treatments for rare disease patients, an increase from six in 2022. Among the newly sanctioned personalized treatments for 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the growing desire for personalized medicine is propelling the growth of the injectable targeted therapy market.
How Is The Injectable Targeted Therapy Market Segmented Across Key Categories?
The injectable targeted therapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types
2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation
3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular
4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications
5) By End User: Hospitals, Specialty Clinics, Research Laboratories
Subsegments:
1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors
3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins
4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics
Which Upcoming Trends Are Expected To Influence The Injectable Targeted Therapy Market?
Leading companies within the injectable targeted therapy market are concentrating on developing innovative approaches, such as subcutaneous injections, to enhance drug delivery efficiency, improve patient compliance, and more effectively target specific disease pathways. Subcutaneous injection refers to a method where medication is administered beneath the skin into the fatty tissue, allowing for slow absorption into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, partnered with Biogen Inc., a US-based biotechnology company, and secured FDA approval for LEQEMBI IQLIK, a therapy for early Alzheimer’s disease. This convenient, once-weekly subcutaneous injection is for the maintenance treatment of early Alzheimer’s disease, empowering patients to self-administer at home after initial intravenous therapy. It contributes to slowing cognitive decline by targeting and clearing amyloid beta plaques and protofibrils, which are key elements driving Alzheimer’s progression. This formulation reduces overall treatment time, decreases systemic side effects compared to IV infusions, and lessens the need for visits to infusion centers, thus offering greater independence for patients and their care partners.
Who Are The Dominant Players Shaping The Injectable Targeted Therapy Market Landscape?
Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.
Read the full injectable targeted therapy market report here:
https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report
Which Region Is Forecast To Lead The Injectable Targeted Therapy Market In Terms Of Market Size?
North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Injectable Targeted Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28250&type=smp
Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Patient Controlled Injectors Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-controlled-injectors-global-market-report
Injectable Drug Delivery Devices Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model